Interview with the Innovators

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans

Tycel J. Phillips, MD
Clinical Associate Professor
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Peg Rummel, MHA, RN, OCN, NE-BC
Oncology Nurse Navigator
Hematology/Head & Neck Clinical Services
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Andrew D. Zelenetz, MD, PhD
Medical Oncologist and Medical Director
Quality Informatics, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Chair, Lymphoma Research Foundation, Scientific Advisory Board
New York, NY

Dr Tycel Phillips discusses the rationale of an “active surveillance” paradigm following initial diagnosis of follicular lymphoma (FL), as well as how to best select patients in whom this approach could be optimally applied, especially considering FL is currently still an incurable disease. Dr Andrew Zelenetz commented on the multifactorial nature of the decision to implement active surveillance, especially in patients who have responded well overall to a first-line regimen but are at risk for relapse (which is a universally expected event, given adequate time). Dr Zelenetz mentioned that clinical acumen and experience, along with consensus criteria (GELF), provide means by which to decide about the timing and choice of agent/regimen for further treatment. Ms Peg Rummel acknowledged the role of nurses and nurse navigators in having patients understand, accept, and embrace active surveillance; educating around further changes in the plan of care and reinforcing that plan; and aiming for optimal outcomes and quality of life in patients with relapsed or refractory FL.

Supported by

Related Articles